Abstract：
BACKGROUND: Budesonide and tixocortol pivalate as markers of contact allergy to corticosteroids have been questioned, as they are not able to detect a significant percentage of allergic patients.
OBJECTIVE: To investigate the potential role of clobetasol propionate in enhancing corticosteroid sensitisation detection.
METHODS: Between January 2022 and December 2023, patients who attended centres involved in the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy were tested with an extended baseline series that included budesonide, tixocortol pivalate, clobetasol propionate 0.1% in ethanol and 1% in petrolatum.
RESULTS: A total of 4338 patients were tested. Twenty-four patients were allergic to budesonide (0.55%, 95% CI: 0.37-0.82); nine patients were allergic to tixocortol pivalate (0.21%, 95% CI: 0.11-0.39); and 23 patients were allergic to clobetasol (0.53%, 95% CI: 0.35-0.79). Only four of those patients allergic to clobetasol were detected by budesonide and one by tixocortol pivalate. No significant differences in the number of positive tests were found between clobetasol in petrolatum or ethanol.
CONCLUSIONS: In Spain budesonide remains the main corticosteroid allergy marker whereas the role of tixocortol pivalate is questionable. The addition of clobetasol propionate to the Spanish baseline series would improve the ability to detect patients allergic to corticosteroids.
OBJECTIVE: To investigate the potential role of clobetasol propionate in enhancing corticosteroid sensitisation detection.
METHODS: Between January 2022 and December 2023, patients who attended centres involved in the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy were tested with an extended baseline series that included budesonide, tixocortol pivalate, clobetasol propionate 0.1% in ethanol and 1% in petrolatum.
RESULTS: A total of 4338 patients were tested. Twenty-four patients were allergic to budesonide (0.55%, 95% CI: 0.37-0.82); nine patients were allergic to tixocortol pivalate (0.21%, 95% CI: 0.11-0.39); and 23 patients were allergic to clobetasol (0.53%, 95% CI: 0.35-0.79). Only four of those patients allergic to clobetasol were detected by budesonide and one by tixocortol pivalate. No significant differences in the number of positive tests were found between clobetasol in petrolatum or ethanol.
CONCLUSIONS: In Spain budesonide remains the main corticosteroid allergy marker whereas the role of tixocortol pivalate is questionable. The addition of clobetasol propionate to the Spanish baseline series would improve the ability to detect patients allergic to corticosteroids.
摘要：
背景：布地奈德和新戊酸替索可托作为皮质类固醇接触过敏的标志物受到质疑，因为他们无法检测到相当比例的过敏患者。
目的：探讨丙酸氯倍他索在增强皮质类固醇致敏检测中的潜在作用。
方法：在2022年1月至2023年12月之间，参加西班牙接触性皮炎和皮肤过敏研究注册中心的患者接受了包括布地奈德在内的扩展基线系列测试，新戊酸替索可托，丙酸氯倍他索0.1%的乙醇和1%的凡士林。
结果：共检查了4338例患者。24例患者对布地奈德过敏(0.55%,95％CI：0.37-0.82）；9例患者对新戊酸替索可托醇过敏（0.21％，95％CI：0.11-0.39）；23例患者对氯倍他索过敏（0.53％，95%CI：0.35-0.79）。布地奈德检测到对氯倍他索过敏的患者中只有4例，新戊酸替索可托检测到1例。凡士林或乙醇中的氯倍他索之间的阳性试验数量没有显着差异。
结论：在西班牙，布地奈德仍然是主要的皮质类固醇过敏标志物，而新戊酸替索可托的作用值得怀疑。在西班牙基线系列中添加丙酸氯倍他索将提高检测对皮质类固醇过敏的患者的能力。
目的：探讨丙酸氯倍他索在增强皮质类固醇致敏检测中的潜在作用。
方法：在2022年1月至2023年12月之间，参加西班牙接触性皮炎和皮肤过敏研究注册中心的患者接受了包括布地奈德在内的扩展基线系列测试，新戊酸替索可托，丙酸氯倍他索0.1%的乙醇和1%的凡士林。
结果：共检查了4338例患者。24例患者对布地奈德过敏(0.55%,95％CI：0.37-0.82）；9例患者对新戊酸替索可托醇过敏（0.21％，95％CI：0.11-0.39）；23例患者对氯倍他索过敏（0.53％，95%CI：0.35-0.79）。布地奈德检测到对氯倍他索过敏的患者中只有4例，新戊酸替索可托检测到1例。凡士林或乙醇中的氯倍他索之间的阳性试验数量没有显着差异。
结论：在西班牙，布地奈德仍然是主要的皮质类固醇过敏标志物，而新戊酸替索可托的作用值得怀疑。在西班牙基线系列中添加丙酸氯倍他索将提高检测对皮质类固醇过敏的患者的能力。
